Accuri Cytometers announces completion of $6 million Series E preferred stock financing Accuri Cytometers, Inc., a worldwide world head in providing life research researchers with easy-to-use, cost-effective stream cytometers, today announced completion of a $6 million Series E preferred stock financing more info . Plan co-handled by Credit Suisse. An interview with Dr Matt SilverHPV research partnership signed between Beckman Coulter and IncellDxImproved results yielded from brand-new ChIP-seq process’Fueled by our continuing sales growth in the U.S. And Europe and our recent expansion into international markets in Asia and SOUTH USA, Accuri is now one of the fastest growing cell analysis companies worldwide,’ said Jeffrey Williams, President and CEO of Accuri.’ Accuri is currently implementing an ISO13485 Quality System in planning for the planned European start of the Accuri C6 Flow Cytometer with CE-IVD mark qualification for clinical make use of, to be followed by a 510 regulatory submission to the meals & Drug Administration seeking clearance to advertise the Accuri C6 Flow Cytometer for scientific IVD applications in the U.S.
While those ongoing wellness reforms do not apply to undocumented immigrants, co-authors Stevens and Michael R. Cousineau, Dr.P.H., associate professor of analysis in the Keck School’s Department of Family Medicine, were tasked with analyzing the efficacy of Healthy Children, a decade-old county-led plan that provides affordable health insurance for children of low-income families who don’t be eligible for state insurance programs like Medi-Cal and Healthy Family members – namely, undocumented children. At the time of data collection in ’09 2009, Healthy Kids was offered in 24 of 58 California counties, providing about 70,700 children statewide with extensive medical, dental and vision insurance coverage. The researchers surveyed 4,011 children from 21 of the 24 Healthful Kids programs .